We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-29.74%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
-$369M
(-60%)
Cap. Flow
-$216M
Cap. Flow
% of AUM
-88.84%
Top 10 Holdings %
Top 10 Hldgs %
9.9%
Holding
504
New
52
Increased
49
Reduced
307
Closed
94
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oxford Square Capital
OXSQ
|
+$1.88M |
| 2 |
Newmont
NEM
|
+$1.81M |
| 3 |
Brookfield Renewable
BEP
|
+$1.69M |
| 4 |
XRN
Chiron Real Estate Inc
XRN
|
+$1.68M |
| 5 |
Public Storage
PSA
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Reliance Steel & Aluminium
RS
|
+$4.3M |
| 2 |
Vale
VALE
|
+$4.14M |
| 3 |
DEA
Easterly Government Properties
DEA
|
+$4.07M |
| 4 |
NP
Neenah, Inc. Common Stock
NP
|
+$4.04M |
| 5 |
Arbor Realty Trust
ABR
|
+$3.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.56% |
| 2 | Healthcare | 19.87% |
| 3 | Real Estate | 12.49% |
| 4 | Energy | 9.44% |
| 5 | Materials | 6.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
CytomX Therapeutics
CTMX
$690M
| $385K | 0.16% |
50,226
-7,311
| -13% | -$51K |
|
202
Corbus Pharmaceuticals
CRBP
$165M
| $374K | 0.15% |
2,378
-347
| -13% | -$58.7K |
|
|
RARX
203
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $365K | 0.15% |
7,612
-1,123
| -13% | -$52.2K |
|
204
Vanda Pharmaceuticals
VNDA
$304M
| $364K | 0.15% |
35,168
-2,968
| -8% | -$36.8K |
|
|
WPG
205
DELISTED
Washington Prime Group Inc.
WPG
| $364K | 0.15% |
+50,288
| New | +$1.18M |
|
|
AKRO
206
DELISTED
Akero Therapeutics
AKRO
| $362K | 0.15% |
17,057
-2,474
| -13% | -$53.1K |
|
207
Ascendis Pharma A/S
ASND
$16.5B
| $351K | 0.14% |
3,117
-452
| -13% | -$58.7K |
|
208
TG Therapeutics
TGTX
$8.19B
| $350K | 0.14% |
35,606
-5,183
| -13% | -$65.5K |
|
|
APLS
209
DELISTED
Apellis Pharmaceuticals
APLS
| $348K | 0.14% |
12,996
-1,892
| -13% | -$67.2K |
|
|
ODT
210
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $343K | 0.14% |
12,410
-1,819
| -13% | -$53K |
|
|
IMGN
211
DELISTED
Immunogen Inc
IMGN
| $342K | 0.14% |
100,431
-14,644
| -13% | -$64K |
|
|
RDUS
212
DELISTED
Radius Health, Inc.
RDUS
| $342K | 0.14% |
26,290
-2,219
| -8% | -$39.6K |
|
213
Arvinas
ARVN
$530M
| $341K | 0.14% |
8,462
-1,236
| -13% | -$57.8K |
|
|
SWTX
214
DELISTED
SpringWorks Therapeutics
SWTX
| $336K | 0.14% |
12,448
-1,805
| -13% | -$58.8K |
|
|
ADVM
215
DELISTED
Adverum Biotechnologies
ADVM
| $333K | 0.14% |
3,411
-497
| -13% | -$57.9K |
|
216
Denali Therapeutics
DNLI
$3.79B
| $333K | 0.14% |
19,020
-2,785
| -13% | -$58.1K |
|
|
ICPT
217
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $325K | 0.13% |
5,156
-435
| -8% | -$39.1K |
|
218
AnaptysBio
ANAB
$1.54B
| $323K | 0.13% |
22,855
-3,331
| -13% | -$50.5K |
|
|
ARNA
219
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $321K | 0.13% |
7,650
-1,108
| -13% | -$50.8K |
|
|
KDMN
220
DELISTED
Kadmon Holdings, Inc.
KDMN
| $318K | 0.13% |
76,008
-11,086
| -13% | -$47.7K |
|
|
EPZM
221
DELISTED
Epizyme, Inc
EPZM
| $315K | 0.13% |
20,306
-2,966
| -13% | -$63.7K |
|
222
Zymeworks
ZYME
$1.62B
| $304K | 0.13% |
8,557
-1,252
| -13% | -$51.2K |
|
|
YMAB
223
DELISTED
Y-mAbs Therapeutics
YMAB
| $296K | 0.12% |
11,332
-1,671
| -13% | -$48.5K |
|
224
Ardelyx
ARDX
$1.24B
| $292K | 0.12% |
51,359
-7,493
| -13% | -$50.9K |
|
|
CLVS
225
DELISTED
Clovis Oncology, Inc.
CLVS
| $291K | 0.12% |
45,754
-3,861
| -8% | -$31K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2020 Portfolio in Review
As of Q1 2020, Virtus ETF Advisers held 504 positions worth $243M, down 60% from $612M the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
Virtus ETF Advisers withdrew a net $216M in Q1 2020, closing 94 positions and reducing 307 holdings. Its most notable exit was Reliance Steel & Aluminium, an estimated $4.3M position sold in full.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Real Estate.
Against the trend, Virtus ETF Advisers opened a new position in Newmont worth $1.82M.
- Virtus ETF Advisers's largest Q1 2020 buy was Newmont: 40,138 shares worth $1.82M.
- Virtus ETF Advisers added most to Oxford Square Capital in Q1 2020, an estimated $1.88M increase.
- Virtus ETF Advisers's biggest Q1 2020 reduction was Air Products & Chemicals, cutting an estimated $3.72M.
- Virtus ETF Advisers fully exited Reliance Steel & Aluminium in Q1 2020, selling an estimated $4.3M.
- Virtus ETF Advisers's ten largest holdings make up 9.9% of its $243M portfolio in Q1 2020.
- Virtus ETF Advisers opened 52 new positions and closed 94 in Q1 2020.
- Virtus ETF Advisers's portfolio value fell 60% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q1 2020, filed 14 May 2020.